Murrayafoline A [CAS 4532-33-6]

Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF) -stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS -induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer[1][2][3][4].

[4532-33-6]

C14H13NO

211.26

CC1=CC2=C(C(=C1)OC)NC3=CC=CC=C23

IKK; Interleukin Related; JNK; NF-κB; p38 MAPK; Wnt; β-catenin

99.73

DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature

H341, H351, H413

H341, H351, H413